Semaglutide is a single GLP-1 receptor agonist, Tirzepatide is a dual GLP-1/GIP agonist, and Retatrutide is a triple GLP-1/GIP/glucagon agonist
mediated through MC4R Cardiovascular : Reports of blood pressure changes, particularly with higher doses Erections : Spontaneous erections in male users, particularly during initial dosing Injection site : Reactions common with subcutaneous administration Regulatory warnings : TGA (Australia), EMA, and other agencies have issued warnings about unregulated MT-2 use PT-141 Side Effects# PT-141's side effect profile is better characterized through Phase 3 data: Nausea : Most common adverse event (~40% of patients in trials)
Research Evidence Comparison# Mazdutide Research# Mazdutide has the largest Phase 3 evidence base of any GLP-1/glucagon dual agonist, with seven trials across the GLORY (obesity) and DREAMS (T2D) programs
Results vary depending on your starting weight, lifestyle, and how consistently you follow your treatment plan
While specific information about Retatrutide is limited, early data suggest its potential for significant weight loss
